The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,670.00
Bid: 1,670.50
Ask: 1,671.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.03%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,670.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Markets pull back from five-month high as banks fall

Wed, 23rd Oct 2013 11:15

Concerns over the Chinese economy and a weak performance by banking stocks halted a nine-day winning streak for UK markets on Wednesday, as investors chose to take profits following a strong run.The FTSE 100 snapped a nine-day winning streak this morning, pulling back from Tuesday's finish of 6,695.66, the index's highest closing high since May 28th when it closed at 6,762.01.Stocks have surged over the past week as investors celebrated the end to the US government shutdown and the short-term deal to raise the debt ceiling. Meanwhile, hopes over a continuation of Federal Reserve monetary stimulus were sparked yesterday after a disappointing September jobs report.Weighing on markets this morning was a sharp sell-off across Asian indices overnight on the back of concerns over the Chinese banking sector following a report that said that debt write-offs at the country's biggest lenders tripled in the first half. Investors were also focusing on the People's Bank of China's decision on Wednesday to refrain from adding liquidity to the market through new reverse repurchase operations, which led to a sharp increase in the country's benchmark money market rate. In other news, the minutes of the latest Bank of England meeting were released this morning and showed that the Monetary Policy Committee was unanimous in its decision to keep policy unchanged as recent economic data pointed to a "robust recovery in activity".Banks, ex-div stocks provide a dragBanks all over Europe were out of favour after the European Central Bank said it would start to review the balance sheets of 130 institutions across the continent. RBS, Barclays, Lloyds, HSBC and Standard Chartered were all registering losses in London.A number of stocks were also trading in the red after going ex-dividend, including Smiths Group, BAE System, Rolls-Royce, John Menzies, Senior, William Hill, Rank Group, Barratt Developments and JD Wetherspoon.Banknote printer and ID services firm De La Rue was a big mover with shares sinking after the company warned that it would miss its full-year profit target by £10m owing to "challenging trading conditions".Drugs group GlaxoSmithKline was also weighing on the market ahead of the release of its third-quarter results due out later on amid concerns over the impact of a corruption probe in China on sales.Chip designer ARM Holdings fell for the second straight day as investors gave a cool reaction to its third-quarter results. JPMorgan Cazenove said this morning that it sees "no reason to be building positions at this time and would take profits in the short term."Sports Direct edged higher after saying that sales in the nine weeks to September 29th were up 15.1% despite some tough comparatives with last year. Fellow retailer Home Retail also rose after a 53% jump in first-half profits owing to sales growth at its Argos and Homebase chains.Costa and Premier Inn owner Whitbread was lower after Deutsche Bank downgraded the stock to 'hold', saying that it's time to "consolidate and take stock" after a great year.Meanwhile, telecoms firm Vodafone was in demand as speculation continues to ramp up about a possible bid from US counterpart AT&T. Credit Suisse has raised its target for the UK-listed stock, saying it sees a 50% chance of a bid.FTSE 100 - RisersRSA Insurance Group (RSA) 127.00p +2.50%Persimmon (PSN) 1,244.00p +1.39%International Consolidated Airlines Group SA (CDI) (IAG) 363.80p +1.34%Travis Perkins (TPK) 1,804.00p +1.23%United Utilities Group (UU.) 713.50p +1.21%Resolution Ltd. (RSL) 351.40p +1.15%Legal & General Group (LGEN) 212.40p +1.14%Capita (CPI) 985.50p +1.13%Shire Plc (SHP) 2,521.00p +1.12%Weir Group (WEIR) 2,361.00p +1.11%FTSE 100 - FallersSmiths Group (SMIN) 1,394.00p -4.19%Anglo American (AAL) 1,510.00p -2.96%Antofagasta (ANTO) 878.00p -2.88%Royal Bank of Scotland Group (RBS) 353.20p -2.43%Rio Tinto (RIO) 3,187.00p -2.28%CRH (CRH) 1,513.00p -2.07%ARM Holdings (ARM) 983.50p -2.04%BHP Billiton (BLT) 1,914.50p -1.85%Barclays (BARC) 267.70p -1.80%GlaxoSmithKline (GSK) 1,575.00p -1.62%FTSE 250 - RisersLaird (LRD) 239.90p +6.29%Pace (PIC) 303.80p +4.76%Home Retail Group (HOME) 191.60p +3.96%African Barrick Gold (ABG) 172.60p +3.35%Kenmare Resources (KMR) 22.48p +3.26%IP Group (IPO) 145.90p +3.04%Alent (ALNT) 363.00p +2.25%Chemring Group (CHG) 219.80p +2.19%Telecom Plus (TEP) 1,514.00p +2.16%BH Global Ltd. USD Shares (BHGU) 11.63 +2.02%FTSE 250 - FallersDe La Rue (DLAR) 889.50p -9.33%International Personal Finance (IPF) 622.00p -6.96%Premier Oil (PMO) 323.10p -4.97%Telecity Group (TCY) 786.00p -4.96%Centamin (DI) (CEY) 49.65p -4.24%Evraz (EVR) 129.50p -3.50%Kazakhmys (KAZ) 253.40p -3.28%AZ Electronic Materials SA (DI) (AZEM) 288.80p -2.43%Soco International (SIA) 405.20p -1.89%Hansteen Holdings (HSTN) 106.00p -1.85%BC
More News
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.